FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types

SNT Gatchaman · Oct 3, 2023

https://www.fda.gov/news-events/pre...est-assess-predisposition-dozens-cancer-types

“This test can assess multiple genes in a single test by using next-generation sequencing, which has proven helpful in providing insight into genetic variants with sensitivity and speed,” said Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health.
Click to expand...

Along with this De Novo authorization, the FDA is establishing special controls that define the requirements related to labeling and performance testing. For example, accuracy for reporting of substitutions, insertions/deletions and copy number variants must be ≥99.0% for positive agreement and ≥99.9% for negative agreement with a validated orthogonal method. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for tests of this type.

Today’s action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through FDA’s 510(k) premarket process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device, which may save a developer time and expense compared to other review pathways.
Click to expand...

Log in or Sign up

FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types

SNT Gatchaman Senior Member (Voting Rights) Staff Member

Share This Page

Log in or Sign up

FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types

SNT Gatchaman Senior Member (Voting Rights) Staff Member

Share This Page

Useful Searches